The NORDIC NEC study found a lower ORR to predominantly platinum-based chemotherapy in patients with a Ki-67 index < 55% (15% versus 42%, p < 0.001) (Sorbye et al. 2013). Here, MKI67 is linked to neuroendocrine carcinoma.